{"id":23868,"date":"2024-07-09T11:12:55","date_gmt":"2024-07-09T15:12:55","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23868"},"modified":"2026-04-25T10:23:32","modified_gmt":"2026-04-25T14:23:32","slug":"unified-patent-court-reshapes-european-patent-landscape","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/unified-patent-court-reshapes-european-patent-landscape\/","title":{"rendered":"The UPC Playbook: European Patent Strategy, IP Valuation, and What Pharma Gets Wrong About Central Revocation"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that date as a distant regulatory footnote are now navigating live consequences: pan-European injunctions filed in Munich local division, central revocation actions targeting blockbuster biologics at the Paris Central Division, and opt-out clocks ticking on transitional-period patents that cover hundreds of millions in annual European revenue.<\/p>\n\n\n\n

This guide covers the full strategic picture. It goes deeper than most UPC overviews because the stakes for biopharma IP holders are materially different from those in other technology sectors. A software company that loses a patent in central revocation loses one asset. A pharma company that loses the European composition-of-matter patent on a biologic blockbuster in a single UPC proceeding loses exclusivity in 18 markets simultaneously, potentially erasing a decade of SPCs and $4-8 billion in projected revenue from DCF models.<\/p>\n\n\n\n

Every section below is written for pharma IP counsel, portfolio managers, R&D leads, and institutional investors who need operational precision, not orientation.<\/p>\n\n\n\n

\n\n\n\n

I. What the UPC Actually Changed, and Why Pre-2023 European Patent Strategy No Longer Works<\/strong><\/h2>\n\n\n\n

The Old System: Fragmented by Design<\/strong><\/h3>\n\n\n\n

Before June 2023, enforcing a European patent across multiple EU markets required parallel national litigation. An originator defending a biologic in Germany, France, the Netherlands, and Italy against a biosimilar entrant filed four separate actions, retained four national counsel teams, briefed four different bench compositions with different evidentiary standards, and waited for four potentially inconsistent outcomes. Courts in the Netherlands historically moved fast; German bifurcation created timing gaps that biosimilar entrants exploited; Italian courts moved slowly enough that launch-at-risk strategies became viable.<\/p>\n\n\n\n

This fragmentation benefited sophisticated generics and biosimilar challengers who could file validity attacks in the most favorable national jurisdictions, obtain an invalidity ruling, and use that holding as commercial leverage in others. For originators, the asymmetry was real: successful enforcement required wins in every major market, while challengers needed only one significant invalidity to restructure licensing negotiations.<\/p>\n\n\n\n

The EPO opposition procedure provided a single validity challenge mechanism, but EPO oppositions have a distinct timeline, average four to six years through appeal, and do not produce injunctions or damages. National courts ran parallel to EPO oppositions, sometimes producing conflicting national validity rulings while an EPO appeal remained pending.<\/p>\n\n\n\n

The New System: Centralized Enforcement and Centralized Risk<\/strong><\/h3>\n\n\n\n

The UPC’s Agreement on a Unified Patent Court (UPCA) created a single court with jurisdiction over Unitary Patents from grant, and jurisdiction over traditional European Patents that have not been opted out. The court’s geographic scope currently covers 18 EU member states. Spain and Poland are not parties. The UK departed through Brexit. Switzerland and Norway remain outside.<\/p>\n\n\n\n

This creates a court with jurisdiction over a market representing roughly 75% of EU pharmaceutical revenues. Getting an injunction at Munich local division or Dusseldorf local division now stops sales across 18 countries with one order. Filing a central revocation action at the Paris or Munich Central Division attacks validity across those same 18 countries with one set of written submissions.<\/p>\n\n\n\n

That symmetry is the entire strategic calculus of the UPC. Every portfolio decision, every opt-out choice, every litigation filing strategy flows from it.<\/p>\n\n\n\n

The 18-Month Data: Adoption Faster Than Expected<\/strong><\/h3>\n\n\n\n

By February 2025, the EPO had registered over 48,000 Unitary Patents. In 2024, 28,125 unitary effect requests were filed. These numbers confirm that the UPC did not experience the slow adoption many predicted during its gestation period. Pharmaceutical and biotech filers are actively using the Unitary Patent track, not defaulting to traditional European Patents plus national validation out of inertia.<\/p>\n\n\n\n

Case filings corroborate this. By mid-September 2023, three months after launch, 37 infringement actions and seven revocation actions had been filed. The infringement-to-revocation ratio, roughly 83:17, held through the UPC’s first full year of operation. The court’s 2024 annual caseload data shows continued growth in both dockets.<\/p>\n\n\n\n

The practical reading for pharma IP teams: the UPC is operationally mature enough to produce first-instance decisions, preliminary injunctions, and early revocation rulings. It is no longer a system to monitor; it is a system to operate within.<\/p>\n\n\n\n

\n\n\n\n

II. The Unitary Patent as a Pharmaceutical IP Asset: Valuation, Structure, and the All-or-Nothing Risk<\/strong><\/h2>\n\n\n\n

How the Unitary Patent Changes IP Asset Valuation<\/strong><\/h3>\n\n\n\n

A traditional European Patent validated in, say, Germany, France, the UK, Italy, and Spain was legally five separate national rights. Each right had its own renewal obligation, its own validity presumption under national law, and its own litigation exposure. The asset was a bundle. In IP valuation frameworks, that bundle is typically modeled as a sum-of-countries DCF, discounted separately for each jurisdiction’s patent term, regulatory data protection, and competitive exposure.<\/p>\n\n\n\n

A Unitary Patent covering 18 participating states is a single right. This changes the valuation architecture in two directions.<\/p>\n\n\n\n

On the upside, a single Unitary Patent covering 18 markets has higher gross exclusivity value than a traditional European Patent validated in four or five countries. Originator companies with broad market ambitions can protect revenue across the full EU participating-state bloc without managing separate national prosecution or renewal fee schedules. The EPO’s Unitary Patent fee structure is designed to approximate the cost of validating and maintaining a traditional European Patent in four to five major countries. For any portfolio strategy requiring protection in six or more UPC states, the Unitary Patent is economically efficient on a per-country basis.<\/p>\n\n\n\n

On the downside, that single right concentrates invalidation risk. In a traditional European Patent portfolio, a generic challenger conducting an invalidity campaign faces the coordination cost of attacking validity in multiple jurisdictions. The attacker must file separate actions, obtain separate rulings, and wait for each national proceeding to conclude. Even a successful invalidity ruling in Germany does not automatically void the French national patent. Each country falls separately. The originator can often defend some markets even after losing others.<\/p>\n\n\n\n

With a Unitary Patent, a central revocation action at the Paris or Munich Central Division, if successful, voids the patent across all 18 participating states simultaneously. IP valuations for Unitary Patents must therefore incorporate a materially higher central revocation probability, applied to the full 18-state revenue base, rather than country-specific probabilities applied to individual national revenues.<\/p>\n\n\n\n

For institutional investors and licensing teams running royalty-rate negotiations, this distinction is not academic. A compound with $600 million in annual European revenues split across a traditional EP bundle validated in six countries has a different risk profile than the same compound protected by a single Unitary Patent. Both may show the same gross exclusivity date, but the Unitary Patent holder faces binary all-or-nothing risk in central revocation, while the EP bundle holder faces attenuated, country-by-country risk. Risk-adjusted NPVs differ accordingly.<\/p>\n\n\n\n

The All-or-Nothing Principle and Pharmaceutical Portfolio Design<\/strong><\/h3>\n\n\n\n

In pharmaceutical patent strategy, the all-or-nothing principle reshapes how originators should think about patent family architecture.<\/p>\n\n\n\n

A well-constructed pharmaceutical patent family typically includes a composition-of-matter patent (the core molecular entity), formulation patents covering specific drug delivery systems or dosage forms, manufacturing process patents, method-of-use patents covering specific therapeutic indications, and dosing regimen patents. Each layer has different claim breadth, different prosecution histories, and different expected validity durability.<\/p>\n\n\n\n

Under the old system, an originator could protect each layer through separate national validations. If a generic challenger successfully invalidated a formulation patent in Germany, the composition-of-matter patent remained valid in Germany independently. Challengers had to work through each layer in each country.<\/p>\n\n\n\n

Under the UPC, an originator holding Unitary Patents across multiple layers of the same drug’s patent family faces a different attack surface. A central revocation action against the Unitary Patent covering the composition-of-matter claim, if successful, removes protection for that molecular entity across all 18 states at once. The formulation Unitary Patent may survive separately, but the primary economic asset, the molecule itself, is exposed.<\/p>\n\n\n\n

This risk profile pushes pharmaceutical IP teams toward two distinct portfolio design responses. First, designating only the strongest, most defensible patent layers as Unitary Patents while opting out patents with potential claim validity weaknesses, preserving those as national EP bundles where validity attacks must be fought jurisdiction by jurisdiction. Second, structuring the patent family so that no single Unitary Patent holds the entire economic value of the compound; the commercial monopoly should rest on multiple overlapping assets with staggered expiry, so that a central revocation of one does not collapse the full exclusivity position.<\/p>\n\n\n\n

This is essentially a pharmaceutical-specific application of IP portfolio theory: diversify the exclusivity asset base to avoid single-point-of-failure exposure.<\/p>\n\n\n\n

Supplementary Protection Certificates Interact with Unitary Patents<\/strong><\/h3>\n\n\n\n

The interaction between Unitary Patents and Supplementary Protection Certificates (SPCs) is a live legal question with major pharmaceutical implications. SPCs extend market exclusivity beyond the 20-year patent term to compensate for the time spent in clinical development and regulatory review. In Europe, SPCs are governed by Regulation (EC) No 469\/2009 and are issued by national patent offices on the basis of a granted European Patent.<\/p>\n\n\n\n

A Unitary SPC regulation has been under development, but the national SPC system based on the underlying granted patent remains operative. Pharmaceutical companies holding Unitary Patents are currently filing for national SPCs in each participating state where they require SPC protection. This means the SPC remains a national right, not a unitary one, creating a structural mismatch: the underlying patent is a single right across 18 states, but the SPC extensions protecting the final years of exclusivity, often the most commercially valuable period for specialty drugs, remain national rights that must be managed individually.<\/p>\n\n\n\n

Central revocation of the Unitary Patent base patent could have cascading consequences for dependent national SPCs. Legal opinions on this question diverge, and UPC jurisprudence has not yet resolved it definitively. IP teams holding major pharmaceutical assets with both Unitary Patent and SPC coverage should not assume SPC survival after central revocation of the base patent without current legal analysis.<\/p>\n\n\n\n

Investment Strategy: Valuing Pharma IP in the UPC Era<\/strong><\/h3>\n\n\n\n

For portfolio managers and institutional investors assessing pharmaceutical companies, the UPC changes how European patent assets should appear in IP valuation models.<\/p>\n\n\n\n

Any pharmaceutical asset holding a Unitary Patent as its primary exclusivity mechanism requires a reassessed central revocation risk factor in DCF models. The probability of central revocation is not equivalent to the sum of country-by-country invalidity probabilities under the old EP bundle system. Central revocation risk under the UPC is elevated because a single well-funded challenger can attack the full European position with one coordinated action rather than distributing resources across multiple national jurisdictions. Challenger economics improve; defender complexity increases.<\/p>\n\n\n\n

Companies with robust patent portfolios covering multiple independent layers of the same drug, each separately opted-out or filed as Unitary Patents based on claim strength, present lower single-asset revocation risk than companies holding a single Unitary Patent as the sole basis for European exclusivity. Patent portfolio architecture should now appear explicitly in pharmaceutical company due diligence, not just patent expiry dates.<\/p>\n\n\n\n

Key Takeaways: Unitary Patent and IP Valuation<\/strong><\/h3>\n\n\n\n

The Unitary Patent provides administratively efficient broad EU coverage but concentrates invalidity risk in a way that materially differs from traditional EP bundle valuation. IP models for pharmaceutical assets must distinguish between Unitary Patent and EP bundle structures when assessing central revocation probability and its revenue impact. SPC-Unitary Patent interactions remain legally unsettled and represent a specific due diligence risk for assets in their peak exclusivity period. Portfolio architecture with multiple overlapping patent layers, each assessed individually for UPC vs. national-court optimal placement, reduces single-point-of-failure exposure.<\/p>\n\n\n\n

\n\n\n\n

III. Biologics, Biosimilars, and the UPC: Where the Stakes Are Highest<\/strong><\/h2>\n\n\n\n

Why the UPC Matters More for Biologics Than Small Molecules<\/strong><\/h3>\n\n\n\n

The pharmaceutical asset class most affected by the UPC’s central revocation risk is large-molecule biologics. This is not primarily because of the inherent complexity of biologic patents, though that complexity is real. It is because of the economic structure of biologic exclusivity and the specific behavior of biosimilar challengers.<\/p>\n\n\n\n

A small-molecule drug’s primary exclusivity anchor is typically the composition-of-matter patent on the active pharmaceutical ingredient. That patent has a standard 20-year term from filing, often extended by SPC. Generics challenge it through Paragraph IV equivalents in national systems or through EPO oppositions. The invalidity attack targets a relatively narrow set of claims on a chemically defined molecule.<\/p>\n\n\n\n

Biologic drugs rely on overlapping exclusivity mechanisms: the composition-of-matter patent on the amino acid sequence or glycoprotein structure, process patents on the cell culture and purification methodology, formulation patents, and regulatory data exclusivity under Article 14(11) of Regulation (EC) No 726\/2004, which grants eight years of data protection plus two years of marketing exclusivity. This layered protection structure is often called the biologic ‘patent thicket.’<\/p>\n\n\n\n

Biosimilar applicants challenging biologic exclusivity under the European regulatory framework file an application demonstrating biosimilarity to the reference biologic. They do not need to prove patent invalidity to receive regulatory approval. Patent enforcement by the originator runs separately from the biosimilarity assessment at EMA. This structural separation means that a biosimilar can receive a positive EMA opinion while the originator’s patents remain valid and enforceable.<\/p>\n\n\n\n

Under the pre-UPC system, an originator defending a biologic against a biosimilar challenger had to file infringement actions country by country as the biosimilar applicant sought to launch in each national market. German courts moved faster; Dutch courts were accessible for pan-EU injunctions in some cases; French and Italian courts were slower. The geographic patchwork created opportunities for biosimilar challengers to launch in some markets while litigation in others remained pending.<\/p>\n\n\n\n

The UPC changes this materially. An originator with a non-opted-out European Patent or a Unitary Patent covering the biologic can file a single infringement action at Munich or Dusseldorf local division and obtain a preliminary injunction that blocks launch across all 18 participating states. A single order, filed and argued in one proceeding, stops the full European biosimilar campaign.<\/p>\n\n\n\n

Biologic Patent Thicket Strategy Under the UPC: A Technology Roadmap<\/strong><\/h3>\n\n\n\n

Biologic originators facing the UPC’s new enforcement architecture need to redesign their patent thicket strategy across multiple dimensions.<\/p>\n\n\n\n

The first layer of the thicket, the composition-of-matter patent covering the biologic molecule, is the primary asset. For IgG monoclonal antibodies, this typically covers the complementarity-determining region (CDR) sequences, the variable domain structure, and in some cases the full antibody sequence. For fusion proteins, the claim structure defines the specific fusion architecture. These are the patents that biosimilar challengers will prioritize attacking in central revocation actions, because eliminating the composition-of-matter patent at UPC removes the originator’s ability to obtain pan-European injunctions based on the molecule itself.<\/p>\n\n\n\n

Originator IP strategy should assess the validity of composition-of-matter patents in the UPC’s legal framework before deciding whether to file them as Unitary Patents or opt out. The UPC’s Articles of Protocol and Rules of Procedure apply a novelty and inventive step analysis that draws on EPO case law, but the court’s technically qualified judges can engage with prior art more substantively than many national courts. A composition-of-matter patent on a biologic that would survive a German national validity challenge may face more rigorous scrutiny at the UPC Central Division.<\/p>\n\n\n\n

The second layer, manufacturing process patents, requires separate analysis. Bioprocessing patents covering upstream cell culture conditions, bioreactor parameters, downstream purification sequences, and viral inactivation steps are notoriously difficult to enforce because biosimilar manufacturers can often design around specific process claims while producing a molecule that meets the biosimilarity standard. These patents typically provide competitive delay, not durable exclusivity. Their opt-out or Unitary Patent designation is a secondary priority.<\/p>\n\n\n\n

The third layer, formulation patents covering specific excipient compositions, pH ranges, or drug delivery mechanisms, can extend effective exclusivity into the post-composition-of-matter-patent period. For subcutaneous delivery formulations of biologics that were originally intravenous, formulation patents are often independently valid and commercially significant. Under the UPC, these patents can be individually designated as Unitary Patents or opted out based on their own validity durability, not bundled with the composition-of-matter patent’s designation.<\/p>\n\n\n\n

The fourth layer, method-of-use patents covering specific approved indications or patient subpopulations, sits at the most contested validity frontier. EPO examination of method-of-use claims requires that the new therapeutic use is not obvious from the prior art and that the clinical evidence in the filing supports the utility asserted. UPC Central Division revocation jurisprudence on method-of-use validity for biologics will develop through early cases and will materially influence how originators value and defend these patents.<\/p>\n\n\n\n

Biosimilar Challenger Strategy: Using the UPC Offensively<\/strong><\/h3>\n\n\n\n

The UPC creates opportunities for biosimilar developers that did not exist under the fragmented national system.<\/p>\n\n\n\n

A biosimilar developer seeking to enter the European market prior to expiry of the originator’s composition-of-matter patent can file a central revocation action at the UPC Central Division before or concurrent with regulatory filing at EMA. This approach, a biosimilar central revocation strategy, allows the challenger to attack validity across all 18 UPC states in a single proceeding rather than deploying country-by-country invalidity campaigns.<\/p>\n\n\n\n

The procedural economics favor this approach. A central revocation action at the Paris or Munich Central Division requires one set of legal submissions, one technical brief, and one oral argument. The challenger’s legal spend on a single UPC central revocation action is substantially lower than the aggregate cost of parallel national invalidity proceedings in Germany, France, Italy, the Netherlands, and Belgium. If the central revocation succeeds, the entire European market opens simultaneously.<\/p>\n\n\n\n

The risk is corresponding. If the central revocation fails and the originator’s composition-of-matter patent survives, the originator can immediately file an infringement action in a local division, seeking a preliminary injunction against the biosimilar launch across all 18 states. The challenger has no fallback position in individual countries where it might have survived a weaker national invalidity defense.<\/p>\n\n\n\n

This creates a game-theoretic dynamic: biosimilar challengers with high confidence in invalidity will prefer central revocation. Challengers with more marginal invalidity arguments may retain country-by-country strategies through the transitional period, accepting the higher cost in exchange for jurisdiction-specific variation in invalidity thresholds.<\/p>\n\n\n\n

Key Takeaways: Biologics and Biosimilar Strategy<\/strong><\/h3>\n\n\n\n

The UPC’s pan-European preliminary injunction power gives biologic originators a stronger enforcement position against biosimilar launch than was available under the fragmented national system. Biosimilar challengers with strong invalidity arguments can use central revocation to attack the full EU market in a single proceeding, dramatically improving challenger economics. Biologic patent thickets should be assessed layer by layer for UPC vs. national court designation, with composition-of-matter patents receiving the most intensive validity review before Unitary Patent filing. The SPC-Unitary Patent interaction for biologics in their peak exclusivity window remains legally unsettled and demands current counsel opinion before finalizing portfolio strategy.<\/p>\n\n\n\n

\n\n\n\n

IV. The Opt-Out Decision: Mechanics, Pharma-Specific Factors, and the Dynamic Strategy Framework<\/strong><\/h2>\n\n\n\n

How Opt-Out Works and the Transitional Period Timeline<\/strong><\/h3>\n\n\n\n

The UPCA provides a transitional period of seven years from June 1, 2023. During this period, ending no earlier than June 1, 2030, potentially extended to 14 years by unanimous decision of the UPC Administrative Committee, proprietors of traditional European Patents may register an opt-out with the UPC Registry. An opted-out patent stays within national court jurisdiction. The UPC has no jurisdiction over an opted-out patent for infringement or revocation.<\/p>\n\n\n\n

An opt-out can be registered at any time during the transitional period, unless national court proceedings have already commenced on the patent at the UPC. There is no fee for registering an opt-out. The process is patent-by-patent through the UPC case management system, and opt-outs can be filed for granted patents, pending European patent applications, and supplementary protection certificates where the underlying patent is a traditional European Patent.<\/p>\n\n\n\n

A registered opt-out is revocable. The proprietor can withdraw the opt-out at any time, bringing the patent back under UPC jurisdiction, as long as no national court proceedings have commenced on that patent after the opt-out was registered. This two-way optionality is strategically significant. It allows a portfolio manager to register an opt-out as a defensive default position during the transitional period and then withdraw the opt-out selectively, for a specific patent, when the enforcement or litigation context warrants it.<\/p>\n\n\n\n

The sunrise period preceding the June 2023 UPC launch allowed provisional opt-outs before the court opened. By launch day, approximately 420,000 opt-outs had been filed. By mid-September 2023, this number reached roughly 560,000. These numbers reflect a portfolio-wide default-to-opt-out approach by a significant segment of patent holders in the early months, consistent with cautious behavior when facing a new court whose jurisprudence was unknown.<\/p>\n\n\n\n

Pharmaceutical-Specific Opt-Out Factors<\/strong><\/h3>\n\n\n\n

For pharmaceutical companies, the opt-out decision has dimensions that do not apply to other technology sectors.<\/p>\n\n\n\n

The first is the patent’s position in the product lifecycle. A composition-of-matter patent with 10-plus years of remaining term and a drug producing $500 million in annual European revenues is in a very different position than a formulation patent with three years of remaining term on a mature product. For high-revenue assets with long remaining terms, the central revocation risk from remaining under UPC jurisdiction may outweigh the enforcement efficiency gain. Opting out preserves national court jurisdiction and forces any challenger to attack validity country by country through the transitional period.<\/p>\n\n\n\n

The second factor is the SPC coverage. If national SPCs have been granted on top of the European Patent, opting out the base patent also affects the relationship between that patent and its SPCs. Since SPCs are national rights, they are not directly opted out, but their enforcement and validity in national proceedings may be intertwined with the base patent’s status.<\/p>\n\n\n\n

The third factor is whether the patent has already been opposed at the EPO. European Patents under opposition or in EPO appeal are not at immediate central revocation risk from the UPC. The EPO opposition procedure runs independently. But once an EPO opposition concludes with the patent maintained, that patent is a candidate for UPC central revocation actions by parties who were not EPO opponents or who want to re-attack validity with UPC-specific procedural tools.<\/p>\n\n\n\n

The fourth factor, specific to biologics, is the relationship between the patent and biosimilar applications currently pending at EMA. If a biosimilar applicant has received a positive EMA opinion and is approaching national launch decisions, the originator’s opt-out or non-opt-out status determines the enforcement venue. An originator that has not opted out a composition-of-matter patent can file a single UPC infringement action seeking a pan-European preliminary injunction. An originator whose patent is opted out must file separate national infringement actions in each country where the biosimilar is approaching launch.<\/p>\n\n\n\n

The Dynamic Opt-Out Strategy: A Staged Framework<\/strong><\/h3>\n\n\n\n

Given the revocability of opt-outs, the appropriate approach for most pharmaceutical portfolios is a staged dynamic strategy rather than a binary opt-out-everything or opt-out-nothing choice at the start of the transitional period.<\/p>\n\n\n\n

Stage one is portfolio segmentation. Categorize each European Patent by asset tier (primary composition-of-matter, secondary formulation\/process\/method-of-use), revenue contribution, remaining term, claim strength, and known or likely challenger landscape. Patents on high-revenue assets with marginal claim strength should be priority opt-out candidates. Patents on high-revenue assets with strong, well-examined claims and no pending EPO opposition are candidates for UPC jurisdiction, given the enforcement upside.<\/p>\n\n\n\n

Stage two is transitional-period default opt-out for uncertain assets. Register opt-outs for patents where the validity assessment is uncertain or where the patent is in a claim family that has faced prior challenges. This costs nothing and preserves maximum flexibility. The opt-out can be withdrawn if enforcement opportunity arises.<\/p>\n\n\n\n

Stage three is selective opt-out withdrawal for enforcement events. When a specific enforcement event occurs, a biosimilar launch, a generic filing, a competitor’s product launch that reads on a specific patent claim, evaluate whether withdrawing the opt-out for that patent to access UPC enforcement is strategically superior to proceeding in national courts. If UPC local division enforcement offers a faster preliminary injunction with broader geographic scope than any national alternative, withdraw the opt-out and file.<\/p>\n\n\n\n

Stage four is continuous jurisprudence monitoring. As UPC case law develops through 2025 and 2026, the court’s validity standards, preliminary injunction thresholds, and revocation success rates will become clearer. Portfolio segmentation criteria should be re-evaluated annually against emerging UPC precedent.<\/p>\n\n\n\n

Key Takeaways: Opt-Out Strategy<\/strong><\/h3>\n\n\n\n

The opt-out is a revocable, cost-free option that should be used selectively based on patent claim strength, revenue contribution, and the specific challenger landscape. A blanket opt-out-everything approach sacrifices enforcement upside; a blanket stay-under-UPC approach exposes weak patents to central revocation. The dynamic staged framework, defaulting to opt-out for uncertain assets while preserving the ability to withdraw for enforcement events, fits most pharmaceutical portfolio structures. SPC and biosimilar regulatory timeline interactions require case-by-case analysis before finalizing any opt-out decision.<\/p>\n\n\n\n

\n\n\n\n

V. UPC Litigation Mechanics: What Pharma IP Counsel Needs to Know<\/strong><\/h2>\n\n\n\n

Court Structure and Division Selection<\/strong><\/h3>\n\n\n\n

The UPC’s Court of First Instance operates through Local Divisions in individual member states, Regional Divisions serving multi-state areas, and the Central Division with seats in Paris and Munich. The Court of Appeal sits in Luxembourg.<\/p>\n\n\n\n

For pharmaceutical patent holders, the relevant enforcement venues are the local divisions. Munich local division and Dusseldorf local division have dominated early infringement case volume, consistent with Germany’s longstanding role as the primary European patent enforcement forum. The Hamburg and Mannheim local divisions have also been active. The Paris local division is the main alternative outside Germany.<\/p>\n\n\n\n

For central revocation and declarations of non-infringement, the Central Division handles actions where no infringement action is pending. Once an infringement action is filed at a local division, a counterclaim for revocation in that same action is referred either to the Central Division or heard at the local division, depending on the local division’s election.<\/p>\n\n\n\n

Forum selection in pharmaceutical cases should incorporate at least four criteria. First, speed: Munich and Dusseldorf divisions have demonstrated the fastest preliminary injunction timelines. Second, technical bench experience: local divisions with technically qualified judges who have life sciences backgrounds will engage more substantively with complex biologic patent claims. Third, bifurcation practice: the UPC system permits bifurcation of infringement and validity proceedings, similar to the German national system. Divisions that bifurcate readily create timing gaps where an infringement ruling precedes the validity determination, which favors originators with strong infringement reads but uncertain validity. Divisions that prefer joint infringement and validity proceedings reduce bifurcation risk for both parties. Fourth, language: proceedings can be conducted in the language of the local division, typically the language of the member state, or in the language in which the patent was granted. For patents granted in English, proceedings at Munich, Paris, or other divisions can be in English where the division agrees, reducing translation burden.<\/p>\n\n\n\n

Preliminary Injunctions in Pharmaceutical Disputes<\/strong><\/h3>\n\n\n\n

The UPC’s ability to grant preliminary injunctions with pan-European effect is the most commercially significant procedural tool for pharmaceutical originators. A preliminary injunction from a local division blocks the infringing product from sale across all 18 UPC participating states while the main action is pending.<\/p>\n\n\n\n

The threshold for a UPC preliminary injunction draws on the court’s own Rules of Procedure, but early decisions indicate that the court applies a standard requiring the applicant to show a prima facie case of infringement, demonstrate urgency, and establish that the balance of hardship favors injunctive relief. The patent must not be manifestly invalid. This ‘manifestly invalid’ standard for PI proceedings is lower than the full validity assessment in the main action, but it is not a rubber stamp. If a biosimilar or generic challenger can produce credible prior art or claim construction arguments at the PI stage, the court may decline to grant interim relief pending trial.<\/p>\n\n\n\n

For biosimilar disputes specifically, the urgency requirement demands that the originator file promptly after learning of the infringing activity or the imminent launch. A pharmaceutical company that monitors EMA biosimilar application databases, which publish biosimilar application acceptance and positive committee opinions, can establish the timeline needed to demonstrate urgency. Companies that delay after becoming aware of an imminent biosimilar launch risk the court finding that urgency has not been established, which could defeat the PI application even where infringement and validity are strong.<\/p>\n\n\n\n

Central Revocation: The Procedural Mechanics Challengers Use<\/strong><\/h3>\n\n\n\n

A central revocation action at the UPC Central Division, filed by a generic or biosimilar company seeking to enter the European market, follows a specific procedural sequence. The challenger files a revocation action with grounds, typically non-novelty or lack of inventive step over specified prior art. The patent holder files a defense and optionally a counterclaim for infringement, though counterclaims for infringement in Central Division revocation actions redirect the infringement component to the relevant local division. Written rounds of submissions follow, with an interim conference and then an oral hearing. First-instance decisions at the Central Division target a 12-month timeline from filing.<\/p>\n\n\n\n

For pharmaceutical originators, the asymmetric risk in central revocation is that a challenger with strong prior art, a sound claim construction argument, and well-prepared technical submissions can run a single coordinated 12-month proceeding that removes European patent protection across 18 countries. The originator defending must produce technically rigorous written submissions on novelty and inventive step across all prior art cited, prepare expert declarations from technical experts qualified in the relevant pharmaceutical science, and argue claim construction in a forum that applies EPO claims interpretation conventions but may approach prosecution history differently than EPO boards.<\/p>\n\n\n\n

Cost-shifting at the UPC means that the losing party bears a portion of the winning party’s legal costs, capped by reference to the dispute’s value. In high-value pharmaceutical patent disputes, cost-shifting can reach substantial amounts. A challenger that initiates central revocation and loses may face six-figure or seven-figure cost orders. This creates a natural selection mechanism: challengers who file central revocation actions will tend to be those with high conviction in their invalidity arguments, or those with sufficient financial resources to absorb an adverse cost order.<\/p>\n\n\n\n

Standard Essential Patents, FRAND, and Pharmaceutical Biosimilar License Negotiations<\/strong><\/h3>\n\n\n\n

The UPC is positioned to become a key FRAND and standard essential patent (SEP) adjudication venue. For the pharmaceutical sector, the direct SEP relevance is limited, but the UPC’s developing jurisprudence on licensing disputes, reasonable royalty determinations, and injunction threshold in licensing contexts will influence how the court approaches license disputes in pharma contexts, including situations where an originator seeks injunctive relief against a biosimilar while a licensing negotiation is ongoing.<\/p>\n\n\n\n

Specifically, where a biosimilar developer seeks a license under an originator’s Unitary Patents before or after central revocation, the UPC’s approach to injunction relief pending license negotiation, and its approach to determining reasonable royalty rates, will inform settlement dynamics. Originators structuring their European licensing strategy for biosimilar market entry should monitor early UPC decisions involving license disputes closely.<\/p>\n\n\n\n

Key Takeaways: UPC Litigation Mechanics<\/strong><\/h3>\n\n\n\n

Munich and Dusseldorf local divisions dominate early infringement case volume and offer the fastest preliminary injunction timelines for pharma patent holders. The pan-European preliminary injunction is the most commercially powerful tool under the UPC, but the urgency requirement demands prompt filing; EMA biosimilar application monitoring creates the tracking infrastructure necessary to establish the timeline. Central revocation at the Paris or Munich Central Division is the primary offensive tool for generic and biosimilar challengers, producing a 12-month first-instance decision that either clears or maintains the European patent position. Cost-shifting in high-value pharmaceutical patent disputes can produce substantial financial consequences for losing challengers or patent holders, creating a natural selection for well-grounded litigation positions.<\/p>\n\n\n\n

\n\n\n\n

VI. Evergreening Strategies and the UPC: How the New Court Changes Lifecycle Management<\/strong><\/h2>\n\n\n\n

Evergreening Tactics and Their UPC Vulnerability<\/strong><\/h3>\n\n\n\n

Pharmaceutical evergreening, the practice of filing secondary patents on modified formulations, new dosing regimens, new salt forms, new polymorphs, or new indications of an existing drug to extend effective market exclusivity beyond the primary composition-of-matter patent’s expiry, faces a changed risk environment under the UPC.<\/p>\n\n\n\n

Secondary patents have always faced validity challenges in European patent proceedings. EPO oppositions have successfully invalidated secondary patents on dosing regimen grounds, formulation grounds, and polymorph grounds with some regularity, particularly where patent examiners granted claims that did not meet the inventive step standard as rigorously as primary composition-of-matter patents. National courts in some EU jurisdictions have applied a more skeptical inventive step analysis to secondary pharmaceutical patents.<\/p>\n\n\n\n

The UPC Central Division, with its technically qualified judiciary, is positioned to apply a rigorous and consistent inventive step analysis to secondary pharmaceutical patents across all participating states. Early indications from UPC proceedings suggest that the court takes the ‘could-would’ distinction of EPO inventive step analysis seriously and is not lenient toward weak secondary patent claims. For pharmaceutical companies relying on a portfolio of secondary patents to extend blockbuster drug exclusivity into the 2030s, the central revocation risk for each secondary patent must be assessed with this in mind.<\/p>\n\n\n\n

The technology roadmap for evergreening under the UPC era has four elements. First, quality of prosecution: secondary patent applications filed at the EPO for the UPC era should receive the same prosecution rigor as primary patents. Claim drafting should anticipate central revocation challenges. Where prior art creates inventive step risk, the application should be narrowed during prosecution to claims that are defensible rather than pursuing broad claims that will not survive central revocation. Second, patent family fragmentation: where a product’s lifecycle extension relies on multiple secondary patents covering formulation, dosing, and indication separately, each should be assessed for Unitary Patent vs. opt-out designation. A weak polymorph patent that would not survive central revocation should be opted out and defended in national courts where invalidity standards may be less stringent, or where country-by-country attrition limits the challenger’s effective attack. Third, SPC coverage architecture: SPC extensions granted on secondary patents in European markets require the secondary patent to be the ‘basic patent’ covering the product. If the secondary patent is held as a Unitary Patent and that patent is centrally revoked, the SPC built on it in each participating state is at risk. This creates a specific evergreening risk scenario where a successful UPC central revocation removes both the secondary patent and its associated SPCs in 18 markets. Fourth, regulatory data exclusivity as a non-patent buffer: 8+2 data exclusivity under European pharmaceutical law does not require patent coverage. For lifecycle extension strategies, ensuring that regulatory data exclusivity periods are maximized independently of patent coverage provides a non-patent exclusivity layer that cannot be centrally revoked.<\/p>\n\n\n\n

Investment Strategy: Evergreening Risk Assessment for Pharma Assets<\/strong><\/h3>\n\n\n\n

Portfolio managers evaluating pharmaceutical companies with heavy reliance on secondary patents for European revenue protection should build a specific UPC vulnerability analysis into their due diligence framework. For each major asset, map the European patent coverage layer by layer, identify which patents are Unitary Patents or non-opted-out European Patents subject to UPC jurisdiction, assess the relative inventive step strength of secondary patent claims against the EPO’s established ‘could-would’ test, and model the revenue impact of a successful central revocation of the most commercially significant secondary patent.<\/p>\n\n\n\n

Companies that have relied on formulation or polymorph patents to extend European exclusivity on mature products, and have filed those patents as Unitary Patents without rigorous pre-filing validity assessment, carry concentrated UPC central revocation risk that should appear as a specific line item in any acquisition or investment due diligence.<\/p>\n\n\n\n

Key Takeaways: Evergreening and Lifecycle Management<\/strong><\/h3>\n\n\n\n

Secondary pharmaceutical patents held as Unitary Patents face a materially higher central revocation risk than primary composition-of-matter patents, because secondary patent inventive step is inherently more vulnerable to challenge. The UPC Central Division’s technically qualified judiciary applies a rigorous inventive step standard that may be more demanding than some national courts. Evergreening strategies in the UPC era require a selective Unitary Patent vs. opt-out designation by patent quality, not blanket designation for the whole product family. Revenue models built on secondary patents for European exclusivity extension through the 2030s should incorporate specific UPC central revocation scenarios.<\/p>\n\n\n\n

\n\n\n\n

VII. Non-Participating States, Hybrid Portfolio Strategy, and the Post-Brexit UK Dimension<\/strong><\/h2>\n\n\n\n

The Geographic Incomplete Coverage Problem<\/strong><\/h3>\n\n\n\n

The UPC covers 18 EU member states. This is not the full map of European pharmaceutical markets. Spain, Poland, and other EU member states that have not ratified the UPCA remain outside UPC jurisdiction. For those markets, European Patents continue to be enforced and challenged exclusively through national courts.<\/p>\n\n\n\n

The UK, following Brexit, is not a UPC participant and cannot join without a new international agreement. The UK patent market remains commercially significant for pharmaceutical companies, particularly in high-value branded drug segments. Post-Brexit UK pharmaceutical patent litigation occurs in the UK Intellectual Property Enterprise Court, the Patents Court of the High Court, and the Court of Appeal. UK patent law is based on the Patents Act 1977 as it applied before UK departure from the EU; it does not automatically track UPC jurisprudence.<\/p>\n\n\n\n

This creates a structural geographic complexity that will not resolve within the current transitional period. An originator with a European Patent that is a Unitary Patent covering 18 UPC states still needs a separate UK patent, validated from the European Patent under the national route, to have enforceable rights in the UK. A biosimilar challenger seeking pan-European market entry must account for separate UK patent proceedings if the originator holds UK patent rights.<\/p>\n\n\n\n

Switzerland and Norway, as non-EU EEA members, are also outside UPC jurisdiction. Norway’s pharmaceutical market is relatively small, but Switzerland’s market, combined with its role as the headquarters of Novartis, Roche, Lonza, and multiple major biotech companies, makes Swiss patent strategy a non-trivial addition to any European pharmaceutical IP framework.<\/p>\n\n\n\n

The UK Unilateral Consideration<\/strong><\/h3>\n\n\n\n

Discussions of UK accession to the UPC have re-emerged in academic and policy circles through 2024 and into 2025. A 2025 Oxford Law Blog analysis outlined procedural pathways for UK accession, and UK IP policy has shown some interest in the efficiency gains a UPC relationship could offer. Any formal UK-UPC relationship would require primary legislation in the UK and a new international agreement with UPC member states.<\/p>\n\n\n\n

For pharmaceutical IP strategy, UK UPC accession remains a long-term hypothetical, not a near-term planning factor. Teams building European patent strategies through the transitional period, running to at least 2030, should plan on continued UK national court jurisdiction as the primary UK enforcement venue.<\/p>\n\n\n\n

Hybrid Portfolio Strategy for Full European Coverage<\/strong><\/h3>\n\n\n\n

A practical European pharmaceutical patent strategy in the UPC era requires what is best described as a four-zone approach: UPC participating states covered by Unitary Patents or non-opted-out European Patents, UPC participating states where specific patents are opted out and remain under national jurisdiction, non-participating EU member states covered by national validations of the European Patent, and non-EU European markets covered by separate national patent filings.<\/p>\n\n\n\n

Each zone has its own enforcement venue, its own validity challenge pathway, and its own cost structure. Managing this architecture requires patent lifecycle management systems capable of tracking opt-out status, renewal fee deadlines across multiple jurisdictions, SPC coverage and term by country, and active litigation status in each zone.<\/p>\n\n\n\n

Key Takeaways: Geographic Coverage and Hybrid Strategy<\/strong><\/h3>\n\n\n\n

The UPC covers 18 states, not all of Europe. Spain, Poland, the UK, Switzerland, and Norway require separate national patent strategies. UK patent enforcement remains in national courts through at minimum the end of the transitional period. A complete European pharmaceutical patent strategy requires four-zone planning that accounts for UPC jurisdiction, opted-out national jurisdiction, non-UPC EU member state jurisdiction, and non-EU European jurisdiction.<\/p>\n\n\n\n

\n\n\n\n

VIII. SMEs, Biotech Startups, and Accessing UPC Enforcement<\/strong><\/h2>\n\n\n\n

The Cost Reality for Smaller Pharmaceutical Companies<\/strong><\/h3>\n\n\n\n

The UPC was designed with SME access as a stated policy goal. The practical cost reality is more complex for smaller pharmaceutical and biotech companies.<\/p>\n\n\n\n

UPC court fees are structured on a fixed fee plus a value-based fee component. For high-value pharmaceutical patent disputes, court fees alone can reach five figures. Legal costs for a full UPC first-instance proceeding, including written submissions, technical expert declarations, and oral hearing representation, typically run into six-figure or seven-figure territory for complex pharmaceutical cases. Cost shifting means that an SME that loses a UPC action, whether as plaintiff or defendant, may face a significant adverse cost order.<\/p>\n\n\n\n

For biotech companies with a single clinical-stage asset and a handful of European patents, the UPC calculus is different than for a diversified originator. A biotech startup defending a composition-of-matter patent against a central revocation action filed by a better-capitalized biosimilar developer faces existential risk from a single UPC proceeding. The cost of defending is high; the consequence of losing is the loss of European exclusivity across 18 states.<\/p>\n\n\n\n

This asymmetry suggests that SMEs and early-stage biotech companies should systematically opt out their core asset patents during the transitional period, retaining national court jurisdiction where individual country invalidity challenges are more expensive and less coordinated for challengers. The UPC’s enforcement upside, the pan-European preliminary injunction, is less valuable to a company that does not yet have a marketed product than the defensive protection of fragmented national invalidity risk is valuable.<\/p>\n\n\n\n

Biotech companies approaching clinical-stage milestones with potential European launches should re-evaluate this position as they approach market. At the point where pan-European enforcement becomes commercially relevant, the opt-out withdrawal mechanism allows selective re-entry to UPC jurisdiction for specific patents.<\/p>\n\n\n\n

The UPC does offer a Patent Mediation and Arbitration Centre as an alternative dispute resolution option. For smaller companies facing enforcement disputes where the cost of full litigation is prohibitive, the mediation centre provides a lower-cost pathway to dispute resolution, though its uptake in pharma patent disputes remains early-stage.<\/p>\n\n\n\n

\n\n\n\n

IX. Developing UPC Jurisprudence: What to Watch Through 2026 and Beyond<\/strong><\/h2>\n\n\n\n

Early Decisions and Emerging Precedents<\/strong><\/h3>\n\n\n\n

The UPC’s early decisions have addressed a mix of jurisdictional questions, preliminary injunction standards, and procedural matters. By mid-2025, the court had issued first-instance decisions across multiple divisions, establishing initial precedents on claim construction methodology, the standard of proof for manifestly invalid patents at the PI stage, and the procedural consequences of opt-out registration errors.<\/p>\n\n\n\n

For pharmaceutical practitioners, the most important developing jurisprudence covers three areas. First, the application of EPO inventive step doctrine (the ‘problem-solution approach’ and the ‘could-would’ distinction) by UPC panels. Early decisions suggest the court applies EPO principles but that technically qualified judges engage with the science in a way that some national courts do not. Second, the interplay between UPC proceedings and parallel EPO opposition or appeal proceedings. The UPC is not required to stay proceedings pending an EPO appeal, and early cases have tested the court’s discretion on this point. For pharmaceutical patents still subject to EPO opposition, the interaction between the two proceedings creates strategic complexity that requires coordinated management. Third, the standard and scope of preliminary injunctions in pharmaceutical cases, particularly the urgency threshold and the manifestly-invalid assessment when a challenger presents credible prior art at the PI stage.<\/p>\n\n\n\n

What Remains Unsettled<\/strong><\/h3>\n\n\n\n

Several significant legal questions affecting pharmaceutical companies have not yet been resolved by UPC jurisprudence. The legal consequences of a Unitary Patent’s central revocation for national SPCs granted on that patent remain contested in academic commentary and have not been directly adjudicated. The UPC’s approach to product-by-process claims in biologic patents, a claim format commonly used when the biologic molecule cannot be fully characterized by structure alone, requires early clarification. The treatment of divisional patent applications and their relationship to the opt-out status of a parent patent creates technical questions for pharmaceutical companies with complex patent families that have not all received clear answers.<\/p>\n\n\n\n

The Trajectory: Five-Year Outlook<\/strong><\/h3>\n\n\n\n

By 2028, the UPC will have five years of first-instance and appellate decisions from which meaningful jurisprudential patterns will be discernible. Pharmaceutical companies will have granular data on UPC preliminary injunction grant rates in pharmaceutical disputes, central revocation success rates against primary and secondary pharmaceutical patents, cost outcomes in high-value pharmaceutical cases, and the court’s evolving approach to biologic patent complexity.<\/p>\n\n\n\n

The transitional period will approach its initial end date in 2030. Before that date, the UPC Administrative Committee will assess whether to extend the transitional period by an additional seven years. Pharmaceutical companies should monitor this extension decision closely, because the answer determines how long the national court opt-out option remains available. If the transitional period extends to 2037, portfolio managers have a much longer window to maintain dynamic opt-out strategies. If the period ends in 2030 without extension, patents not opted out by that date come permanently under UPC exclusive jurisdiction.<\/p>\n\n\n\n

\n\n\n\n

X. Strategic Recommendations for Pharma IP Teams and Portfolio Managers<\/strong><\/h2>\n\n\n\n

For Originator Pharmaceutical Companies<\/strong><\/h3>\n\n\n\n

Segment the European patent portfolio by asset tier and claim strength before the transitional period ends. Assign opt-out default status to secondary patents with marginal inventive step strength, patents on mature products with limited remaining term, and patents subject to active or foreseeable validity challenges. Reserve Unitary Patent or non-opted-out status for composition-of-matter patents with strong prosecution histories, no pending EPO oppositions, and revenue-significant European coverage. Build a systematic EMA biosimilar application monitoring program to establish the factual record necessary to demonstrate urgency in preliminary injunction applications. Coordinate patent opt-out decisions with SPC coverage analysis to avoid inadvertently destabilizing SPC positions on major assets.<\/p>\n\n\n\n

For Biosimilar and Generic Developers<\/strong><\/h3>\n\n\n\n

Evaluate central revocation as a first-choice strategy against non-opted-out European Patents and Unitary Patents covering reference biologics where invalidity arguments are well-grounded. The economics of a single central revocation action against 18 markets are substantially more favorable than parallel national invalidity proceedings against five to seven countries. Build technical expert relationships with academic and clinical experts qualified in the relevant biological science before filing, because the UPC’s technically qualified judiciary engages substantively with scientific arguments in ways national courts often did not. Monitor opt-out registrations through the UPC Registry to track which originator patents remain under UPC jurisdiction and therefore accessible for central revocation.<\/p>\n\n\n\n

For Institutional Investors<\/strong><\/h3>\n\n\n\n

Request that portfolio companies provide a UPC vulnerability assessment for their top five European revenue assets as part of annual IP reporting. The assessment should identify which patents are Unitary Patents, which are non-opted-out EPs, which have been opted out, and what the revenue exposure is to a successful central revocation of the primary exclusivity patent on each major asset. Do not treat European patent expiry dates as the only exclusivity horizon; model central revocation probability as a separate scenario, particularly for assets in or near the biosimilar challenge window.<\/p>\n\n\n\n

For Licensing and Business Development Teams<\/strong><\/h3>\n\n\n\n

European patent license valuations and royalty rate negotiations must account for the originator’s enforcement position under the UPC. A licensor holding a Unitary Patent on a high-revenue biologic can credibly threaten pan-European preliminary injunctions in license compliance disputes. This enforcement strength supports higher royalty rates and more demanding license terms. Conversely, a licensor whose primary European patents are opted out and whose national enforcement position is fragmented across five jurisdictions has weaker leverage. Understand the specific UPC status of the licensed assets before entering royalty negotiations.<\/p>\n\n\n\n

\n\n\n\n

XI. Key Takeaways: The Full Picture<\/strong><\/h2>\n\n\n\n

The UPC is operational, active, and producing real consequences for pharmaceutical IP strategy. It is not a theoretical future development. Pan-European preliminary injunctions have been filed and granted. Central revocation actions are moving through the Central Division. The opt-out clock is running.<\/p>\n\n\n\n

The system’s defining characteristic is the direct correspondence between enforcement power and revocation risk. The same single proceeding that can produce a pan-European injunction can produce a pan-European revocation. This symmetry means that the strategic question is never simply ‘is this patent strong enough to enforce?’ It is always ‘is this patent strong enough to survive a well-resourced central revocation challenge?’<\/p>\n\n\n\n

Pharmaceutical companies that answer that question rigorously, by asset, by layer, by claim strength, will build portfolio architectures that use the UPC’s enforcement power where they have defensible patents and preserve national court fragmentation where they do not. Companies that apply blanket policies, opt everything out or leave everything in, will either sacrifice enforcement upside or accumulate central revocation exposure on assets that cannot withstand it.<\/p>\n\n\n\n

The transitional period lasts at least until 2030. That is enough time to build and execute a thoughtful dynamic strategy. It is not enough time to continue treating the UPC as a future planning item.<\/p>\n\n\n\n

\n\n\n\n

Data points cited in this analysis are drawn from EPO official statistics, UPC Registry published caseload data, and academic and professional legal commentary cited in the source analysis from DrugPatentWatch.<\/em><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that […]<\/p>\n","protected":false},"author":1,"featured_media":38419,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23868","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=23868"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23868\/revisions"}],"predecessor-version":[{"id":38420,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23868\/revisions\/38420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38419"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=23868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=23868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=23868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}